nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—CYP2C9—Leflunomide—systemic scleroderma	0.105	0.446	CbGbCtD
Guanfacine—CYP2C19—Prednisone—systemic scleroderma	0.0622	0.265	CbGbCtD
Guanfacine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0376	0.16	CbGbCtD
Guanfacine—CYP3A4—Prednisone—systemic scleroderma	0.0301	0.128	CbGbCtD
Guanfacine—CYP2C9—cardial valve—systemic scleroderma	0.0232	0.619	CbGeAlD
Guanfacine—NISCH—smooth muscle tissue—systemic scleroderma	0.00338	0.0901	CbGeAlD
Guanfacine—NISCH—tendon—systemic scleroderma	0.00254	0.0677	CbGeAlD
Guanfacine—NISCH—lung—systemic scleroderma	0.00223	0.0594	CbGeAlD
Guanfacine—ADRA2A—connective tissue—systemic scleroderma	0.00135	0.0359	CbGeAlD
Guanfacine—CYP2C19—digestive system—systemic scleroderma	0.00129	0.0345	CbGeAlD
Guanfacine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00115	0.00158	CcSEcCtD
Guanfacine—Palpitations—Lisinopril—systemic scleroderma	0.00115	0.00158	CcSEcCtD
Guanfacine—Loss of consciousness—Lisinopril—systemic scleroderma	0.00114	0.00157	CcSEcCtD
Guanfacine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00114	0.00156	CcSEcCtD
Guanfacine—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.00114	0.00156	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00113	0.00155	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00112	0.00154	CcSEcCtD
Guanfacine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00153	CcSEcCtD
Guanfacine—Insomnia—Leflunomide—systemic scleroderma	0.00112	0.00153	CcSEcCtD
Guanfacine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00153	CcSEcCtD
Guanfacine—Paraesthesia—Leflunomide—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Guanfacine—Myalgia—Lisinopril—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Guanfacine—Arthralgia—Lisinopril—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Guanfacine—Chest pain—Lisinopril—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Guanfacine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Guanfacine—Anxiety—Lisinopril—systemic scleroderma	0.0011	0.00151	CcSEcCtD
Guanfacine—Dyspnoea—Leflunomide—systemic scleroderma	0.0011	0.00151	CcSEcCtD
Guanfacine—Hypotension—Mycophenolic acid—systemic scleroderma	0.0011	0.00151	CcSEcCtD
Guanfacine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00109	0.0015	CcSEcCtD
Guanfacine—Discomfort—Lisinopril—systemic scleroderma	0.00109	0.0015	CcSEcCtD
Guanfacine—Lethargy—Methotrexate—systemic scleroderma	0.00109	0.0015	CcSEcCtD
Guanfacine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00109	0.0015	CcSEcCtD
Guanfacine—Dyspepsia—Leflunomide—systemic scleroderma	0.00109	0.00149	CcSEcCtD
Guanfacine—Vomiting—Mometasone—systemic scleroderma	0.00108	0.00149	CcSEcCtD
Guanfacine—Dry mouth—Lisinopril—systemic scleroderma	0.00108	0.00149	CcSEcCtD
Guanfacine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00108	0.00148	CcSEcCtD
Guanfacine—Rash—Mometasone—systemic scleroderma	0.00108	0.00148	CcSEcCtD
Guanfacine—Asthenia—Captopril—systemic scleroderma	0.00107	0.00148	CcSEcCtD
Guanfacine—Dermatitis—Mometasone—systemic scleroderma	0.00107	0.00148	CcSEcCtD
Guanfacine—Decreased appetite—Leflunomide—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Confusional state—Lisinopril—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Headache—Mometasone—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Guanfacine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Guanfacine—Fatigue—Leflunomide—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Guanfacine—Oedema—Lisinopril—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Guanfacine—Pruritus—Captopril—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Guanfacine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00106	0.00145	CcSEcCtD
Guanfacine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00145	CcSEcCtD
Guanfacine—Constipation—Leflunomide—systemic scleroderma	0.00106	0.00145	CcSEcCtD
Guanfacine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Guanfacine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Guanfacine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Guanfacine—Shock—Lisinopril—systemic scleroderma	0.00104	0.00143	CcSEcCtD
Guanfacine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00104	0.00142	CcSEcCtD
Guanfacine—Tachycardia—Lisinopril—systemic scleroderma	0.00104	0.00142	CcSEcCtD
Guanfacine—Abdominal pain—Azathioprine—systemic scleroderma	0.00103	0.00142	CcSEcCtD
Guanfacine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00141	CcSEcCtD
Guanfacine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00103	0.00141	CcSEcCtD
Guanfacine—Diarrhoea—Captopril—systemic scleroderma	0.00102	0.00141	CcSEcCtD
Guanfacine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00102	0.00141	CcSEcCtD
Guanfacine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00141	CcSEcCtD
Guanfacine—Irritability—Methotrexate—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Guanfacine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Guanfacine—Erectile dysfunction—Prednisone—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Guanfacine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Guanfacine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00102	0.00139	CcSEcCtD
Guanfacine—Nausea—Mometasone—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Guanfacine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Guanfacine—Weight increased—Prednisone—systemic scleroderma	0.00101	0.00138	CcSEcCtD
Guanfacine—Constipation—Mycophenolic acid—systemic scleroderma	0.00101	0.00138	CcSEcCtD
Guanfacine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00138	CcSEcCtD
Guanfacine—CYP2C9—digestive system—systemic scleroderma	0.001	0.0268	CbGeAlD
Guanfacine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.001	0.00137	CcSEcCtD
Guanfacine—Hypotension—Lisinopril—systemic scleroderma	0.000991	0.00136	CcSEcCtD
Guanfacine—Dizziness—Captopril—systemic scleroderma	0.00099	0.00136	CcSEcCtD
Guanfacine—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000989	0.00136	CcSEcCtD
Guanfacine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000987	0.00136	CcSEcCtD
Guanfacine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000983	0.00135	CcSEcCtD
Guanfacine—Abdominal pain—Leflunomide—systemic scleroderma	0.000976	0.00134	CcSEcCtD
Guanfacine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000974	0.00134	CcSEcCtD
Guanfacine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00097	0.00133	CcSEcCtD
Guanfacine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00133	CcSEcCtD
Guanfacine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00133	CcSEcCtD
Guanfacine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00133	CcSEcCtD
Guanfacine—Myocardial infarction—Prednisone—systemic scleroderma	0.000968	0.00133	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000966	0.00133	CcSEcCtD
Guanfacine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000966	0.00133	CcSEcCtD
Guanfacine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000963	0.00132	CcSEcCtD
Guanfacine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000963	0.00132	CcSEcCtD
Guanfacine—Insomnia—Lisinopril—systemic scleroderma	0.000959	0.00132	CcSEcCtD
Guanfacine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000958	0.00132	CcSEcCtD
Guanfacine—Paraesthesia—Lisinopril—systemic scleroderma	0.000952	0.00131	CcSEcCtD
Guanfacine—Vomiting—Captopril—systemic scleroderma	0.000952	0.00131	CcSEcCtD
Guanfacine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000948	0.0013	CcSEcCtD
Guanfacine—Dyspnoea—Lisinopril—systemic scleroderma	0.000946	0.0013	CcSEcCtD
Guanfacine—Rash—Captopril—systemic scleroderma	0.000944	0.0013	CcSEcCtD
Guanfacine—Dermatitis—Captopril—systemic scleroderma	0.000943	0.0013	CcSEcCtD
Guanfacine—Somnolence—Lisinopril—systemic scleroderma	0.000943	0.0013	CcSEcCtD
Guanfacine—Headache—Captopril—systemic scleroderma	0.000938	0.00129	CcSEcCtD
Guanfacine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000937	0.00129	CcSEcCtD
Guanfacine—Dyspepsia—Lisinopril—systemic scleroderma	0.000934	0.00128	CcSEcCtD
Guanfacine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000931	0.00128	CcSEcCtD
Guanfacine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000929	0.00128	CcSEcCtD
Guanfacine—Asthma—Methotrexate—systemic scleroderma	0.000926	0.00127	CcSEcCtD
Guanfacine—ADRA2A—tendon—systemic scleroderma	0.000925	0.0247	CbGeAlD
Guanfacine—Decreased appetite—Lisinopril—systemic scleroderma	0.000922	0.00127	CcSEcCtD
Guanfacine—Fatigue—Lisinopril—systemic scleroderma	0.000914	0.00126	CcSEcCtD
Guanfacine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000914	0.00126	CcSEcCtD
Guanfacine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000909	0.00125	CcSEcCtD
Guanfacine—Constipation—Lisinopril—systemic scleroderma	0.000907	0.00125	CcSEcCtD
Guanfacine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000907	0.00125	CcSEcCtD
Guanfacine—Bradycardia—Prednisone—systemic scleroderma	0.000903	0.00124	CcSEcCtD
Guanfacine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000898	0.00123	CcSEcCtD
Guanfacine—Diarrhoea—Azathioprine—systemic scleroderma	0.000894	0.00123	CcSEcCtD
Guanfacine—Nausea—Captopril—systemic scleroderma	0.00089	0.00122	CcSEcCtD
Guanfacine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000887	0.00122	CcSEcCtD
Guanfacine—Asthenia—Leflunomide—systemic scleroderma	0.000886	0.00122	CcSEcCtD
Guanfacine—Hallucination—Prednisone—systemic scleroderma	0.000882	0.00121	CcSEcCtD
Guanfacine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000874	0.0012	CcSEcCtD
Guanfacine—Pruritus—Leflunomide—systemic scleroderma	0.000873	0.0012	CcSEcCtD
Guanfacine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000868	0.00119	CcSEcCtD
Guanfacine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000867	0.00119	CcSEcCtD
Guanfacine—Dizziness—Azathioprine—systemic scleroderma	0.000864	0.00119	CcSEcCtD
Guanfacine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000853	0.00117	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000847	0.00116	CcSEcCtD
Guanfacine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000845	0.00116	CcSEcCtD
Guanfacine—Diarrhoea—Leflunomide—systemic scleroderma	0.000845	0.00116	CcSEcCtD
Guanfacine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00084	0.00115	CcSEcCtD
Guanfacine—Abdominal pain—Lisinopril—systemic scleroderma	0.000838	0.00115	CcSEcCtD
Guanfacine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000834	0.00115	CcSEcCtD
Guanfacine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000833	0.00114	CcSEcCtD
Guanfacine—Vomiting—Azathioprine—systemic scleroderma	0.000831	0.00114	CcSEcCtD
Guanfacine—Eye disorder—Prednisone—systemic scleroderma	0.000829	0.00114	CcSEcCtD
Guanfacine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000828	0.00114	CcSEcCtD
Guanfacine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000826	0.00113	CcSEcCtD
Guanfacine—Drowsiness—Methotrexate—systemic scleroderma	0.000825	0.00113	CcSEcCtD
Guanfacine—Rash—Azathioprine—systemic scleroderma	0.000824	0.00113	CcSEcCtD
Guanfacine—Dermatitis—Azathioprine—systemic scleroderma	0.000823	0.00113	CcSEcCtD
Guanfacine—Headache—Azathioprine—systemic scleroderma	0.000819	0.00112	CcSEcCtD
Guanfacine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000818	0.00112	CcSEcCtD
Guanfacine—Dizziness—Leflunomide—systemic scleroderma	0.000816	0.00112	CcSEcCtD
Guanfacine—ADRA2A—lung—systemic scleroderma	0.000811	0.0217	CbGeAlD
Guanfacine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000808	0.00111	CcSEcCtD
Guanfacine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000806	0.00111	CcSEcCtD
Guanfacine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000802	0.0011	CcSEcCtD
Guanfacine—Immune system disorder—Prednisone—systemic scleroderma	0.000801	0.0011	CcSEcCtD
Guanfacine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000795	0.00109	CcSEcCtD
Guanfacine—Sweating—Methotrexate—systemic scleroderma	0.000791	0.00109	CcSEcCtD
Guanfacine—Vomiting—Leflunomide—systemic scleroderma	0.000785	0.00108	CcSEcCtD
Guanfacine—Alopecia—Prednisone—systemic scleroderma	0.000783	0.00108	CcSEcCtD
Guanfacine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000781	0.00107	CcSEcCtD
Guanfacine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000779	0.00107	CcSEcCtD
Guanfacine—Rash—Leflunomide—systemic scleroderma	0.000778	0.00107	CcSEcCtD
Guanfacine—Dermatitis—Leflunomide—systemic scleroderma	0.000778	0.00107	CcSEcCtD
Guanfacine—Nausea—Azathioprine—systemic scleroderma	0.000776	0.00107	CcSEcCtD
Guanfacine—Headache—Leflunomide—systemic scleroderma	0.000773	0.00106	CcSEcCtD
Guanfacine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000766	0.00105	CcSEcCtD
Guanfacine—CYP3A4—digestive system—systemic scleroderma	0.000765	0.0204	CbGeAlD
Guanfacine—Asthenia—Lisinopril—systemic scleroderma	0.000761	0.00105	CcSEcCtD
Guanfacine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00076	0.00104	CcSEcCtD
Guanfacine—Pruritus—Lisinopril—systemic scleroderma	0.00075	0.00103	CcSEcCtD
Guanfacine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000749	0.00103	CcSEcCtD
Guanfacine—Rash—Mycophenolic acid—systemic scleroderma	0.000742	0.00102	CcSEcCtD
Guanfacine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000742	0.00102	CcSEcCtD
Guanfacine—Headache—Mycophenolic acid—systemic scleroderma	0.000738	0.00101	CcSEcCtD
Guanfacine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000735	0.00101	CcSEcCtD
Guanfacine—Nausea—Leflunomide—systemic scleroderma	0.000733	0.00101	CcSEcCtD
Guanfacine—Vision blurred—Prednisone—systemic scleroderma	0.000727	0.000999	CcSEcCtD
Guanfacine—Diarrhoea—Lisinopril—systemic scleroderma	0.000726	0.000997	CcSEcCtD
Guanfacine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000716	0.000984	CcSEcCtD
Guanfacine—Visual impairment—Methotrexate—systemic scleroderma	0.000714	0.000981	CcSEcCtD
Guanfacine—Agitation—Prednisone—systemic scleroderma	0.000709	0.000974	CcSEcCtD
Guanfacine—Dizziness—Lisinopril—systemic scleroderma	0.000701	0.000963	CcSEcCtD
Guanfacine—Nausea—Mycophenolic acid—systemic scleroderma	0.000699	0.000961	CcSEcCtD
Guanfacine—Malaise—Prednisone—systemic scleroderma	0.000696	0.000956	CcSEcCtD
Guanfacine—Vertigo—Prednisone—systemic scleroderma	0.000693	0.000953	CcSEcCtD
Guanfacine—Eye disorder—Methotrexate—systemic scleroderma	0.000692	0.000951	CcSEcCtD
Guanfacine—Syncope—Prednisone—systemic scleroderma	0.000692	0.000951	CcSEcCtD
Guanfacine—Tinnitus—Methotrexate—systemic scleroderma	0.000691	0.000949	CcSEcCtD
Guanfacine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000685	0.00094	CcSEcCtD
Guanfacine—Loss of consciousness—Prednisone—systemic scleroderma	0.000678	0.000932	CcSEcCtD
Guanfacine—Vomiting—Lisinopril—systemic scleroderma	0.000674	0.000926	CcSEcCtD
Guanfacine—Immune system disorder—Methotrexate—systemic scleroderma	0.000669	0.000919	CcSEcCtD
Guanfacine—Rash—Lisinopril—systemic scleroderma	0.000669	0.000919	CcSEcCtD
Guanfacine—Convulsion—Prednisone—systemic scleroderma	0.000669	0.000919	CcSEcCtD
Guanfacine—Dermatitis—Lisinopril—systemic scleroderma	0.000668	0.000918	CcSEcCtD
Guanfacine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000667	0.000916	CcSEcCtD
Guanfacine—Hypertension—Prednisone—systemic scleroderma	0.000666	0.000915	CcSEcCtD
Guanfacine—Headache—Lisinopril—systemic scleroderma	0.000664	0.000913	CcSEcCtD
Guanfacine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000657	0.000903	CcSEcCtD
Guanfacine—Myalgia—Prednisone—systemic scleroderma	0.000657	0.000903	CcSEcCtD
Guanfacine—Arthralgia—Prednisone—systemic scleroderma	0.000657	0.000903	CcSEcCtD
Guanfacine—Anxiety—Prednisone—systemic scleroderma	0.000655	0.000899	CcSEcCtD
Guanfacine—Alopecia—Methotrexate—systemic scleroderma	0.000655	0.000899	CcSEcCtD
Guanfacine—Discomfort—Prednisone—systemic scleroderma	0.000649	0.000892	CcSEcCtD
Guanfacine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000636	0.000873	CcSEcCtD
Guanfacine—Dysgeusia—Methotrexate—systemic scleroderma	0.000632	0.000868	CcSEcCtD
Guanfacine—Nausea—Lisinopril—systemic scleroderma	0.00063	0.000865	CcSEcCtD
Guanfacine—Oedema—Prednisone—systemic scleroderma	0.00063	0.000865	CcSEcCtD
Guanfacine—Shock—Prednisone—systemic scleroderma	0.00062	0.000851	CcSEcCtD
Guanfacine—Tachycardia—Prednisone—systemic scleroderma	0.000615	0.000844	CcSEcCtD
Guanfacine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000614	0.000844	CcSEcCtD
Guanfacine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000609	0.000836	CcSEcCtD
Guanfacine—Vision blurred—Methotrexate—systemic scleroderma	0.000608	0.000835	CcSEcCtD
Guanfacine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000598	0.000822	CcSEcCtD
Guanfacine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000591	0.000812	CcSEcCtD
Guanfacine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000586	0.000805	CcSEcCtD
Guanfacine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000585	0.000804	CcSEcCtD
Guanfacine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000582	0.0008	CcSEcCtD
Guanfacine—Malaise—Methotrexate—systemic scleroderma	0.000582	0.000799	CcSEcCtD
Guanfacine—Vertigo—Methotrexate—systemic scleroderma	0.00058	0.000796	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000574	0.000788	CcSEcCtD
Guanfacine—Insomnia—Prednisone—systemic scleroderma	0.00057	0.000783	CcSEcCtD
Guanfacine—Paraesthesia—Prednisone—systemic scleroderma	0.000566	0.000777	CcSEcCtD
Guanfacine—Convulsion—Methotrexate—systemic scleroderma	0.000559	0.000768	CcSEcCtD
Guanfacine—Dyspepsia—Prednisone—systemic scleroderma	0.000554	0.000762	CcSEcCtD
Guanfacine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000552	0.000758	CcSEcCtD
Guanfacine—Chest pain—Methotrexate—systemic scleroderma	0.000549	0.000754	CcSEcCtD
Guanfacine—Arthralgia—Methotrexate—systemic scleroderma	0.000549	0.000754	CcSEcCtD
Guanfacine—Myalgia—Methotrexate—systemic scleroderma	0.000549	0.000754	CcSEcCtD
Guanfacine—Decreased appetite—Prednisone—systemic scleroderma	0.000548	0.000752	CcSEcCtD
Guanfacine—Fatigue—Prednisone—systemic scleroderma	0.000543	0.000746	CcSEcCtD
Guanfacine—Discomfort—Methotrexate—systemic scleroderma	0.000543	0.000745	CcSEcCtD
Guanfacine—Constipation—Prednisone—systemic scleroderma	0.000539	0.00074	CcSEcCtD
Guanfacine—Confusional state—Methotrexate—systemic scleroderma	0.000531	0.000729	CcSEcCtD
Guanfacine—Feeling abnormal—Prednisone—systemic scleroderma	0.000519	0.000713	CcSEcCtD
Guanfacine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000515	0.000708	CcSEcCtD
Guanfacine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000509	0.000699	CcSEcCtD
Guanfacine—Abdominal pain—Prednisone—systemic scleroderma	0.000498	0.000684	CcSEcCtD
Guanfacine—Hypotension—Methotrexate—systemic scleroderma	0.000492	0.000676	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00048	0.000659	CcSEcCtD
Guanfacine—Insomnia—Methotrexate—systemic scleroderma	0.000476	0.000654	CcSEcCtD
Guanfacine—Paraesthesia—Methotrexate—systemic scleroderma	0.000473	0.000649	CcSEcCtD
Guanfacine—Dyspnoea—Methotrexate—systemic scleroderma	0.000469	0.000645	CcSEcCtD
Guanfacine—Somnolence—Methotrexate—systemic scleroderma	0.000468	0.000643	CcSEcCtD
Guanfacine—Hypersensitivity—Prednisone—systemic scleroderma	0.000464	0.000637	CcSEcCtD
Guanfacine—Dyspepsia—Methotrexate—systemic scleroderma	0.000463	0.000637	CcSEcCtD
Guanfacine—Decreased appetite—Methotrexate—systemic scleroderma	0.000458	0.000629	CcSEcCtD
Guanfacine—Fatigue—Methotrexate—systemic scleroderma	0.000454	0.000623	CcSEcCtD
Guanfacine—Asthenia—Prednisone—systemic scleroderma	0.000452	0.000621	CcSEcCtD
Guanfacine—Pruritus—Prednisone—systemic scleroderma	0.000446	0.000612	CcSEcCtD
Guanfacine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000434	0.000596	CcSEcCtD
Guanfacine—Diarrhoea—Prednisone—systemic scleroderma	0.000431	0.000592	CcSEcCtD
Guanfacine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00043	0.000591	CcSEcCtD
Guanfacine—Dizziness—Prednisone—systemic scleroderma	0.000417	0.000572	CcSEcCtD
Guanfacine—Abdominal pain—Methotrexate—systemic scleroderma	0.000416	0.000572	CcSEcCtD
Guanfacine—Vomiting—Prednisone—systemic scleroderma	0.0004	0.00055	CcSEcCtD
Guanfacine—Rash—Prednisone—systemic scleroderma	0.000397	0.000546	CcSEcCtD
Guanfacine—Dermatitis—Prednisone—systemic scleroderma	0.000397	0.000545	CcSEcCtD
Guanfacine—Headache—Prednisone—systemic scleroderma	0.000395	0.000542	CcSEcCtD
Guanfacine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000388	0.000533	CcSEcCtD
Guanfacine—Asthenia—Methotrexate—systemic scleroderma	0.000378	0.000519	CcSEcCtD
Guanfacine—Nausea—Prednisone—systemic scleroderma	0.000374	0.000514	CcSEcCtD
Guanfacine—Pruritus—Methotrexate—systemic scleroderma	0.000372	0.000512	CcSEcCtD
Guanfacine—Diarrhoea—Methotrexate—systemic scleroderma	0.00036	0.000495	CcSEcCtD
Guanfacine—Dizziness—Methotrexate—systemic scleroderma	0.000348	0.000478	CcSEcCtD
Guanfacine—Vomiting—Methotrexate—systemic scleroderma	0.000335	0.00046	CcSEcCtD
Guanfacine—Rash—Methotrexate—systemic scleroderma	0.000332	0.000456	CcSEcCtD
Guanfacine—Dermatitis—Methotrexate—systemic scleroderma	0.000332	0.000456	CcSEcCtD
Guanfacine—Headache—Methotrexate—systemic scleroderma	0.00033	0.000453	CcSEcCtD
Guanfacine—Nausea—Methotrexate—systemic scleroderma	0.000313	0.00043	CcSEcCtD
